Phase 3 VIKTORIA-2 Study: Fulvestrant & CDK4/6i /- Gedatolisib as 1L Treatment in Patients With HR /HER2- Advanced Breast Cancer
Phase 3 VIKTORIA-2 Study: Fulvestrant & CDK4/6i /- Gedatolis…
5 months ago
vumedi.com
Dr McCann on the Potential Clinical Utility of Gedatolisib in Advanced Breast Cancer | OncLive
1:51
Dr McCann on the Potential Clinical Utility of Gedatolisib in Advanced …
4 months ago
onclive.com
Celcuity Inc.: Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium
Celcuity Inc.: Celcuity Presents Overall Survival Data from Phase …
4 months ago
finanznachrichten.de
Celcuity Inc.: Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR /HER2- Advanced Breast Cancer
Celcuity Inc.: Celcuity Announces First Patient Dosed in Phase 3 VIK…
8 months ago
finanznachrichten.de
Dr Han on the Investigation of Gedatolisib in HR /HER2– Metastatic Breast Cancer | OncLive
Dr Han on the Investigation of Gedatolisib in HR /HER2– Metastat…
Apr 26, 2023
onclive.com
Celcuity Inc. présente des données précliniques sur les effets thérapeutiques du gédatolisib dans des modèles de cancer du sein lors du 2023 San Antonio Breast Cancer Symposium
Celcuity Inc. présente des données précliniques sur les effets thérape…
Dec 6, 2023
zonebourse.com
Celcuity Inc. Reports Clinical Data from Two Early Phase Studies of Gedatolisib
Celcuity Inc. Reports Clinical Data from Two Early Phase Studies of …
8 months ago
marketscreener.com
Celcuity Inc. Announces FDA Acceptance of New Drug Applicati…
2 months ago
marketscreener.com
0:15
Gedatolisib Regimens Significantly Extend Survival in Advanced Brea…
10 views4 months ago
YouTubeJh Li
1:09
New PI3K Inhibitor Shows Promise for HER2+ Breast Cancer
10 views2 months ago
YouTubeOncology Perspectives
SABCS 2023 Insights: "VIKTORIA-1 Study of Gedatolisib Fulvestrant / …
376 viewsDec 12, 2023
vumedi.com
6:20
CELC Strengthens on Breakthrough Cancer Trial — FDA Approval Next?
22 views5 months ago
YouTubeEquity4keeps
4:34
Trending in Oncology: ENHERTU China 2L gastric approval and more
1 views1 month ago
YouTubeLucidQuest
18:04
Dr. Erika Hamilton | ER+ Metastatic Breast Cancer
34 views3 weeks ago
YouTubeOncoAlert 360
4:13
Sotorasib vs. Adagrasib as Treatment for KRAS G12C Mutate…
903 viewsApr 28, 2023
YouTubeGlobal Resource for Advancing Cancer Education
13:07
MECHANISM OF ACTION: DIGITALIS
11.6K viewsNov 15, 2020
YouTubeGPAT DISCUSSION CENTER
23:34
Metastatic HR+ Breast Cancer SABCS 2025 Highlights: Dr. Hope …
5.7K views2 months ago
YouTubeOncBrothers: Practice-Changing Cancer Discus…
3:49
Navigating TROP2 ADC Options in PD-L1-Negative TNBC
1.7K views2 months ago
YouTubeOncUpdates: Latest Oncology Insights
0:27
የአመት ሰው ይበለን#gedi_b #ገና #አእላፋት_ዝማሬ
19.6K views2 months ago
TikTokgedi_b
5:07
Antibiotic Answers: Gepotidacin
748 views11 months ago
YouTubeCAP Center
6:57
How does Dapagliflozin work? Understanding SGLT2 inhibitors.
213.4K viewsJan 31, 2019
YouTubeZero To Finals
2:31
ESMO 2025 Top 10 Must See Breast Cancer Abstracts
577 views5 months ago
YouTubeOncologyTube
1:07:55
PI3K/ AKT/mTOR Pathway Inhibitors in the Treatment of HR+/HER2- Me…
3K views5 months ago
YouTubeCancerNet Events
21:53
The Role of Sitagliptin in Newly DiagnosedT2DM Patients / Prof In…
362 viewsMar 19, 2023
YouTubeAASD Diabetes
ጊቢ ገብርኤል አባቴ እና ወንበር ቃለ መጻፍ
12.7K views8 months ago
TikTokgedi_b
22:17
Breast Cancer ESMO 2025 Highlights: MonarchE, NATALEE, …
5.9K views4 months ago
YouTubeOncBrothers: Practice-Changing Cancer Discus…
HR /HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathway | On…
Aug 8, 2023
onclive.com
1:23:40
Key Steps to Success With CDK4/6 Inhibition in Early Through Metast…
267 views1 month ago
YouTubePeerView Oncology
1:27
Treatment landscape post-CDK4/6 inhibitors in HR+/HER2-low metast…
74 views3 months ago
YouTubeVJOncology
1:03
Gepotidacin: Phase 3
1.5K views5 months ago
YouTubeLive UTI Free
See more videos
Static thumbnail place holder